Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $187.23M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | Avoro Capi... | avorocapit... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2021 | Series B | $135M | - |
| 28.01.2021 | Series A | $52.23M | - |
Mentions in press and media 17
| Date | Title | Description |
| 17.07.2026 | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. Fri, Jul 17, 2026 08:00 CET Report this content 17 July 2026 THE BIOTECH GROWTH TRUST PLC (“BIOG” or the "Company") Eli Lilly to acquire BIOG portfolio company, AtaiBec... |
| 16.06.2026 | Biotech IPO revival faces competition from cash-rich big pharma buyers | Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan’s top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simu... |
| 10.06.2026 | Podcast: Palantir to sue Sadiq Khan, GSK’s $10bn mega-deal, and could the World Cup rescue pubs? | In today’s episode of City AM’s Business As Usual podcast, we get stuck in the top stories of the day – from a major pharma M&A deal to a US software giant poised to take legal action against the Mayor of London. City Editor Simon Hunt ... |
| 09.06.2026 | GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn | Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was t... |
| 09.06.2026 | More swings for AI stocks drag Wall Street back on the roller coaster | Getting your Trinity Audio player ready... By STAN CHOE, AP Business Writer NEW YORK (AP) — Another sudden reversal for high-flying artificial-intelligence stocks sent Wall Street reeling on Tuesday. The S&P 500 fell 0.3% after careenin... |
| 09.06.2026 | GSK in talks to buy cancer biotech Nuvalent for more than $9 billion | - |
| 09.06.2026 | GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares | GSK has said agentic AI is already affecting every asset in its pipeline, as pharmaceutical firms race to use the technology to cut the cost and risk of developing new medicines. Speaking at London Tech Week in Tuesday, Eyal Itskovitz, GSK’... |
| 09.06.2026 | GSK покупает американскую Nuvalent за $10,6 млрд для усиления онкологического портфеля | Британская фармкомпания GSK договорилась о покупке американского разработчика онкологических препаратов Nuvalent за $10,6 млрд. Это крупнейшая сделка компании более чем за десятилетие и часть стратегии нового CEO Лукаса Мьельса по усилению ... |
| 14.03.2023 | Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 | CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. NUVL, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming pr... |
| 08.09.2021 | Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results |
Show more